Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2.Population...
-
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became...
-
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Diversified Royalty Corp. (TSX: DIV, DIV.DB.A and DIV.DB.B) (the “Corporation” or “DIV”) is pleased to announce its financial results...
-
MISSISSAUGA, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the fourth quarter (Q4) and full year (FY) ended...
-
(Dollar amounts are in thousands, in Canadian currency unless otherwise specified) GUELPH, Ontario, March 19, 2026 (GLOBE NEWSWIRE) -- Hammond Power Solutions Inc. (“HPS” or the “Company”) (TSX:...
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results
-
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Glacier Media Inc. (TSX: GVC) (“Glacier” or the “Company”) reported revenue and earnings for the year ended December 31, 2025. ...
-
HAMILTON, BERMUDA, March 19, 2026 – DHT Holdings, Inc. (NYSE:DHT) (the “Company”) has filed its 2025 annual report on Form 20-F with the U.S. Securities and Exchange Commission (the “SEC”). The...
-
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in...
-
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003...